#tecovirimat

[transparentgentlemenmarker]

Le pneumologue allemand Dr. Wofgang Wodarg annonce : Ce qu'on nous vend comme la variole du singe appelée Monkeypox, actuellement mpox est dans la plupart des cas ce qu'on appelle le zona, l'un des effets secondaires les plus fréquents du vaccin Covid. La variole du 🐵 est commercialisée pour cacher les effets secondaires ❔❔❔

Serait-ce nôtre fin annoncée où un retour aux origines. Les premiers signes peuvent apparaître cela commence par un syndrome grippal une grosse fièvre, des courbatures, des maux de gorge.

Puis des adénopathies, c'est-à-dire des ganglions disséminés, des éruptions cutanées

Il y a deux clades il faut comprendre deux variants du virus qui sont historiquement identifiés. Le clade I est diffusé en Afrique centrale. Le clade II sévit en Afrique de l'Ouest. C'est une maladie virale et d'origine zoonotique. Il existe un antiviral, le tecovirimat

Aux jeunes vous avez la chance de rayer le plus de lignes possible

Préparez-vous à un dépistage de masse

[queerforscience]

"Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other)"

.. and this didn't adjust for HIV status, so given the existing disparities in both HIV prevalence and viral suppression among people living with HIV, Black patients especially in addition to Hispanic and/or Latino/a/x/e patients likely should have received tecovirimat more often than white patients.

[illnessfaker]

thread on mpox (previously known as monkeypox) by a vaccine researcher.

key points:

mpox is not new & it is not like covid

smallpox vaccines are effective against mpox ("at least 86%")

"JYNNEOS (Imvanex, IMVAMUNE) is a non-replicating vaccine for smallpox that CAN BE USED SAFELY in immunocompromised individuals and individuals with skin conditions such as eczema against Mpox"

WHO declared public health emergency status due to surge in cases in & around the DRC (i'm assuming this spread of the disease is linked to the crisis)

"we also have some antiviral drugs (such as Tecovirimat) that can help treat those who are already infected. Vaccinia immune globulin (VIG) can be used against monkeypox"

you should be able to get the jynneos vaccine at your local pharmacy if you are concerned about exposure!

stay safe folks 🫡

[covid-safer-hotties]

Also preserved on our archive (That's right: We do more than just covid!)

By Lisa Schnirring

Genetic sequencing has identified a second cluster of tecovirimat-resistant mpox infections in the United States—the first of its kind involving interstate spread. Researchers from the US Centers for Disease Control and Prevention (CDC) and partners from five affected states reported their findings yesterday in Morbidity and Mortality Weekly Report.

The first Tpoxx-resistant cluster was identified in California in late 2022 and early 2023 in people who hadn't previously been treated with the drug. The new report describes a new unrelated cluster among 18 people with no previous treatment across multiple states.

Sequencing identified a unique combination of resistance mutations in 20 specimens collected from 18 patients between October 2023 and February 2024. The patients were from five states: Illinois (8), California (5), Louisiana (2), Texas (2), and New York (1).

Of 16 patients with an available treatment history, one had received the drug before the sample was collected. Of 17 patients with available clinical data, illnesses were mild and similar to standard clade 2 infections, though two were hospitalized for pain management.

Findings likely underestimate spread of resistant variant In vitro testing of seven samples showed resistance to Tpoxx. Whole-genome sequencing showed that the resistance mutations came from a common ancestor but were distinct from the earlier California cluster.

Researchers said because not all viruses from mpox cases are sequenced, the findings likely underestimate the prevalence of the newly identified drug-resistant variant. They added that more surveillance is needed, as well as adherence to CDC Tpoxx use protocols. Also, they wrote that the findings underscore the need for more treatments for mpox, along with smallpox biothreat preparedness.

Study link: www.cdc.gov/mmwr/volumes/73/wr/mm7340a3.htm?s_cid=mm7340a3_e&ACSTrackingID=USCDC_921-DM138236&ACSTrackingLabel=This%20Week%20in%20MMWR%3A%20Vol.%2073%2C%20October%2010%2C%202024&deliveryName=USCDC_921-DM138236#contribAff

[broadlyepi]

MMWR Booster #6: Clinical and Epidemiologic Characteristics of Mpox Cases from the Initial Phase of the Outbreak — New York City, May 19–July 15, 2022

Top 5 Takeaways:

Demographics and Risk Behaviors: Among 719 mpox patients in NYC, 97.9% were men, predominantly identifying as gay or queer (78.7%), or bisexual (5.6%). A significant proportion reported intimate or sexual contact with men, which appears to have been a key risk factor.

Symptomatology: Prodromal symptoms were noted in 38.1% of cases. Notably, 45.1% reported proctitis or rectal symptoms, with a majority not observing perianal skin lesions. Ophthalmic manifestations were seen in 6.2% of patients.

Diagnostic Delays and Treatment: The median time from symptom onset to diagnosis was 5 days. Tecovirimat was administered to 14.0% of patients, and 4.9% required hospitalization.

Importance of Anorectal Swabs: Over two-thirds of patients with rectal symptoms lacked perianal lesions, suggesting the potential utility of anorectal swabs in diagnosis, despite current protocols focusing on swabbing skin lesions.

Data Completeness and Public Health Implications: Data on gender, race, ethnicity, and sexual orientation were over 80% complete, aiding public health outreach. The study’s findings can inform public health messaging and clinical management strategies.

link: BroadlyEpi.com

[rajco1]

What You Need to Know About Mpox Cases in California

November 17, 2024

Mpox Overview

Definition: Monkeypox virus disease.

Transmission: Skin-to-skin contact, contaminated objects.

Symptoms: Rash, fever, headache and fatigue.

California Mpox Cases

Case Count: 987 confirmed cases (California Department of Public Health).

Regions Affected: Los Angeles, San Francisco, San Diego.

Demographics: Primarily affects men who have sex with men.

Prevention Strategies

Vaccination: JYNNEOS and ACAM2000 vaccines.

Safe Sex Practices: Condoms, gloves.

Hygiene: Frequent handwashing.

Social Distancing: Avoid close contact.

Symptoms and Testing

Early Detection: Monitor for symptoms.

Lab Testing: PCR, serology tests.

Medical Consultation: Immediate evaluation.

Treatment and Care

Antiviral Medication: Tecovirimat.

Supportive Care: Pain management, hydration.

Isolation: Prevent transmission.

[stevenwilliam12]

Monkeypox Market Landscape: Epidemiology, Key Treatments, and 2032 Forecast  

Monkeypox is a viral zoonotic disease caused by the monkeypox virus, part of the orthopoxvirus family, closely related to the variola virus, which causes smallpox. Although historically endemic to parts of Central and West Africa, recent outbreaks have been reported in non-endemic regions, sparking global concern. Symptoms of monkeypox include fever, rash, swollen lymph nodes, and muscle aches. While typically less severe than smallpox, the disease can cause serious complications, particularly in children, pregnant women, and immunocompromised individuals.

Transmission occurs through close contact with an infected person, contaminated surfaces, or respiratory droplets, making person-to-person spread a growing concern. With the re-emergence of cases worldwide, the need for effective vaccines, antiviral medications, and diagnostic tools has become paramount.

Monkeypox Market Insights

Since the global outbreak in 2022, the monkeypox market has grown rapidly, with rising demand for antiviral treatments, vaccines, and diagnostics. Vaccines such as JYNNEOS (by Bavarian Nordic) and ACAM2000, initially developed for smallpox, have been repurposed to protect against monkeypox. Antiviral treatments like Tecovirimat (TPOXX) have also played a crucial role in managing infections, demonstrating effectiveness against orthopoxviruses.

Governments and healthcare organizations have responded by increasing investments in public health infrastructure, diagnostics, and vaccine production to contain outbreaks. The focus on early detection through advanced diagnostic tools has also gained momentum, ensuring faster response to new cases. As awareness grows, the monkeypox market is positioned for continued expansion, with efforts directed toward preparedness and prevention strategies.

Key Players in the Monkeypox Market

Several pharmaceutical companies have taken the lead in developing solutions for the prevention, diagnosis, and treatment of monkeypox. Key players include:

Bavarian Nordic A/S – Developer of the JYNNEOS vaccine

SIGA Technologies, Inc. – Manufacturer of Tecovirimat (TPOXX)

Emergent BioSolutions Inc.

Johnson & Johnson

Novavax, Inc.

GeoVax Labs, Inc.

Chimerix, Inc.

BioCryst Pharmaceuticals, Inc.

Tekmira Pharmaceuticals Corporation

Inovio Pharmaceuticals, Inc.

These companies are focused on scaling up vaccine production, advancing new therapies, and developing cutting-edge diagnostic tools to combat the evolving threat of monkeypox.

Monkeypox Epidemiology Overview

The epidemiology of monkeypox has evolved significantly, with confirmed cases now reported in countries across North America, Europe, and Asia. While the virus was previously confined to specific regions of Africa, increased travel and close-contact activities have contributed to its spread. The shift in transmission patterns has raised concerns about monkeypox becoming a more persistent global health threat.

In response, governments have enhanced surveillance and case reporting efforts to better monitor outbreaks. Comprehensive epidemiological databases have been developed to track case numbers, transmission chains, and population risk factors. High-risk groups, such as healthcare workers, individuals in close-contact environments, and those with pre-existing health conditions, are the primary focus for vaccination and treatment campaigns.

Monkeypox Market Forecast – 2032

The monkeypox market is projected to experience steady growth through 2032, driven by increasing investments in vaccine development, antiviral therapies, and rapid diagnostic tools. Governments are expected to continue allocating resources to outbreak preparedness by stockpiling vaccines, scaling up production, and improving healthcare infrastructure to address future outbreaks.

Key factors contributing to the market’s growth include innovations in vaccine technology, expanded antiviral pipelines, and advancements in diagnostic tools for early detection. Public awareness campaigns, combined with supportive health policies, will further drive the adoption of preventive and therapeutic solutions. Additionally, pharmaceutical companies are expected to accelerate the development of new vaccines and treatments to meet rising demand.

Challenges and Opportunities

Despite the positive growth trajectory, the market faces several challenges, such as supply chain disruptions, limited diagnostic coverage in certain regions, and public hesitancy toward vaccination. However, opportunities also abound, with digital health technologies offering innovative ways to enhance outbreak tracking and patient care.

Collaboration between governments, health organizations, and pharmaceutical companies will be essential in ensuring equitable access to vaccines and treatments. Regulatory support will play a critical role in fast-tracking the development and approval of novel therapies, further accelerating market growth.

Conclusion

The monkeypox market is set for sustained growth through 2032, driven by advancements in vaccines, diagnostics, and therapeutics. As public health systems enhance preparedness, companies ramp up production, and awareness campaigns expand, the global response to monkeypox will become more robust.

With new developments on the horizon and collaborative efforts between governments and pharmaceutical companies, the market will continue to grow. This expansion will improve access to essential tools, enabling better management of monkeypox outbreaks and contributing to greater global health resilience over the coming decade.

Latest Reports Offered By DelveInsight:

Hemodialysis Catheter Market | Vertebral Body Replacement Systems Market | Bronchiectasis Market | Conductive Hearing Loss Market | Erythema Market | Homocystinuria Market | Idiopathic Interstitial Pneumonias Market | Metabolic Syndrome Market | Muscle Invasive Bladder Cancer Market | Myofascial Pain Syndrome Market | Opioid Use Disorder Market | Orthopedic Trauma Devices Market | Post-polycythemia Vera Myelofibrosis Market | Primary Open-angle Glaucoma Market | Seborrhea Market | Undifferentiated Pleomorphic Sarcoma Market | Audiology Devices Market | Ductal Carcinoma In Situ Market | Hemodynamic Monitoring System Market | Synchronous Endometrial And Ovarian Carcinoma Market | Acute Pyelonephritis Market | Adeno-associated Virus Aav Vectors In Gene Therapy Market | Adenosine Deaminase-severe Combined Immunodeficiency Market | Cell And Gene Therapy For Multtiple Myeloma Market

[kazifatagar]

Monkey Pox Vaccines to be Distributed for High-Risk Cases

Health Minister Datuk Seri Dzulkefly Ahmad has confirmed that the monkey pox vaccine will be distributed in Malaysia through the Covid-19 ASEAN Response Fund. He said the MVA-BN vaccine and the Antiviral Tecovirimat (TPOXX) medication will be distributed in the country although he did not disclose when, according to a post on his X account. Monkey Pox vaccines to be distributed for high-risk…

[thenetsight]

Promising Mpox Drug Fails in Trials as Virus Spreads

As mpox continues to spread in Central Africa, a promising antiviral drug to treat the infection has failed to improve patients’ symptoms in a trial in the Democratic Republic of the Congo, the epicenter of the outbreak. In the trial, the drug tecovirimat, also known as TPOXX, did not alleviate the characteristic blisterlike rash seen in people with mpox, formerly known as monkeypox. In an…

[centraldenoticiasmx]

Fármaco contra la cepa de viruela del mono no responde como se espera

🖊#Salud | Fármaco contra la cepa de viruela del mono no responde como se espera +INFO:

Recientes investigaciones pusieron en duda la efectividad de un fármaco utilizado para tratar la viruela del mono, una enfermedad que ganó atención global debido a la propagación de cepas peligrosas en diversas regiones de África. El tecovirimat, antiviral desarrollado inicialmente para combatir la viruela, mostró resultados decepcionantes en un ensayo llevado a cabo en la República Democrática…

[scientificinquirer-blog]

DAILY DOSE: Antiviral Drug Fails to Speed Monkeypox Healing; Global Tourism Surge Brings Growth and Environmental Challenges.

TECOVIRIMAT NOT EFFECTIVE FOR CLADES I MPox PATIENTS A recent clinical trial in the Democratic Republic of the Congo (DRC) revealed that the antiviral drug tecovirimat did not significantly accelerate healing for patients with the clade I strain of monkeypox, which is considered more lethal than clade II. Despite its use in treating mpox, tecovirimat’s effectiveness remains uncertain due to…

[iamnaturalnana]

The FDA Approved an Anti-Bioterrorism Drug Meant to Treat Smallpox

The Food and Drug Administration (FDA) on Friday approved the first drug specifically designed to treat smallpox — despite the fact that the disease was officially eradicated in 1980. While the daily threat of smallpox, which is caused by the variola virus, is virtually non-existent, FDA Commissioner Scott Gottlieb said in a statement that the drug, called TPOXX, or tecovirimat, could be a…

[insideoutvietnam]

SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced today an agreement to expand access to TPOXX (tecovirimat) to the member states in the Association of Southeast Asian Nations (ASEAN), a political and economic union in the region. This agreement, which was signed by the Ministry…

[ccrdvietnam]

Dau Mua Khi Phong Ngua va Dieu Tri Dung Cach

Đậu Mùa Khỉ: Phòng Ngừa và Điều Trị Đúng Cách

Bệnh đậu mùa khỉ là một vấn đề truyền nhiễm nguy hiểm, có khả năng lây lan nhanh chóng qua tiếp xúc giữa người với người. Đối mặt với tình hình này, nhiều người đặt ra câu hỏi: Nếu mắc phải bệnh, liệu chúng ta có thể đối phó và điều trị như thế nào?

Hiện tại, chưa có phương pháp điều trị cụ thể cho bệnh đậu mùa khỉ, và đối mặt với tình hình này, việc chăm sóc bản thân và thực hiện các biện pháp phòng ngừa là quan trọng. Bệnh thường tự giảm đi mà không cần đến điều trị, nhưng nếu triệu chứng trở nên nghiêm trọng, các biện pháp điều trị cần được áp dụng.

Có một số loại thuốc kháng virus như Tecovirimat (TPOXX), Brincidofovir (Tembexa), và Cidofovir được sử dụng để giảm nhẹ triệu chứng và hạn chế các biến chứng bệnh. Tuy nhiên, việc sử dụng thuốc nên được thực hiện dưới sự giám sát của bác sĩ, đặc biệt là đối với những đối tượng có nguy cơ nặng cao như người suy yếu miễn dịch, trẻ em dưới 8 tuổi, và phụ nữ mang thai.

Đối với những trường hợp nghiêm trọng, việc đến bệnh viện để được hỗ trợ điều trị là cần thiết. Các triệu chứng như sốt cao không giảm, mệt mỏi, hôn mê, suy giảm nhận thức đều là dấu hiệu cần lưu ý và đòi hỏi sự can thiệp chuyên sâu từ đội ngũ y tế.

Một điều quan trọng khác là việc cách ly để ngăn chặn sự lây lan của bệnh. Người bệnh cần tuân thủ quy tắc cách ly, nghỉ ngơi đầy đủ, và tránh căng thẳng để hỗ trợ quá trình phục hồi. Dù có hay không áp dụng các loại thuốc điều trị, việc dinh dưỡng cân đối vẫn là yếu tố quan trọng. Ăn uống đầy đủ và đa dạng giúp cơ thể tăng cường sức đề kháng và nhanh chóng phục hồi.

Trong bối cảnh đậu mùa khỉ đang là mối quan tâm toàn cầu, việc hiểu rõ về cách phòng ngừa và điều trị là quan trọng. Hãy chủ động thực hiện các biện pháp an toàn và thảo luận với bác sĩ để có kế hoạch phòng tránh và điều trị hiệu quả nhất. Chăm sóc bản thân, tuân thủ y tế, và đồng lòng đối mặt với thách thức này là cách tốt nhất để bảo vệ sức khỏe của bạn và cộng đồng.

Tham khảo bài viết chi tiết: 50++ Hình Ảnh bệnh đậu mùa khỉ dễ nhận biết qua từng thể

#ccrd #ccrd.org.vn #benhdaumuakhi #hinhanhbenhdaumuakhi

[cavenewstimes]

Monkeypox Has the Potential to Mutate and Resist Antiviral Treatment, FDA Warns

As the international monkeypox break out sticks around on, health authorities are cautioning that the infection is altering at a speed that might quickly permit it to end up being resistant to an antiviral substance abuse to deal with clients at danger of major health problem. The Food and Drug Administration (FDA) is advising that companies be “cautious” in recommending the drug tecovirimat– or…